Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
PHARMACOGENETICS AND GENOMICS（2018）
Key words
allopurinol,cost-effectiveness,genetic testing,HLA-B*58:01,Stevens-Johnson syndrome,toxic epidermal necrolysis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined